Recent Updates
Recently added Catalysts
BIIB Positive Sentiment

Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Thursday, August 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Biogen Inc. announced that its CEO, Christopher A. Viehbacher, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The event is scheduled for September 14, 2026, at 9:15 AM. This participation underscores Biogen's commitment to engaging with the healthcare sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Biogen's participation highlights its engagement with the healthcare community.
  • The event provides a platform for Biogen's leadership to share insights.
  • The fireside chat format encourages open dialogue about Biogen's strategies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis

Full Press Release Details

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the Morgan Stanley 24th Annual Global Healthcare Conference. The webcast will be live on Monday, Sept 14, 2026, at 9:15

Frequently Asked Questions

Who will represent Biogen at the conference?

Christopher A. Viehbacher, the CEO of Biogen, will represent the company.

When is the Morgan Stanley Healthcare Conference?

The conference is scheduled for September 14, 2026.

What format will Biogen's participation take?

Biogen's participation will be in the form of a fireside chat.

What is the significance of this conference for Biogen?

The conference allows Biogen to engage with the healthcare community and share insights.

ShareAdd on Google
Tags: BIIB Viatris Investor Conferences Healthcare Biogen Morgan Stanley healthcare conference Christopher Viehbacher fireside chat
Last updated: Aug 27, 2026

Biotech snapshot

Cash runway
$3878M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AlefaceptPhase 3
Chronic Plaque Psoriasis →

Catalyst track record

+34%
best trade around BIIB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for BIIB.

See every catalyst's timing & PoA →